Table 4.
Associations between demographic and clinical characteristics and risk perceptions.
| Characteristic | Likelihood of progression in two years | Likelihood of progression in five years | Likelihood of progression in 10 years |
|---|---|---|---|
| Male vs. female | 0.10 (−0.24, 0.45) | 0.06 (−0.30, 0.41) | 0.06 (−0.33, 0.45) |
| Age | 0.01 (−0.01, 0.02) | 0.001 (−0.01, 0.01) | −0.01 (−0.03, 0) |
| White race vs. othera | 0.37 (−0.23, 0.97) | 0.05 (−0.55, 0.65) | −0.31 (−1.02, 0.40) |
| Marital status | 0.07 (−0.25, 0.39) | −0.05 (−0.38, 0.27) | −0.10 (−0.46, 0.25) |
| Number of children | 0.07 (−0.06, 0.19) | 0 (−0.13, 0.13) | −0.04 (−0.18, 0.11) |
| EDSS | 0.14 (0.08, 0.21)a | 0.12 (0.06, 0.19)a | 0.13 (0.06, 0.21)a |
| Disease duration | −0.002 (−0.02, 0.01) | −0.01 (−0.02, 0.01) | −0.02 (−0.03, −0.002)a |
| Disease course (progressive vs. relapsing) | 0.71 (0.36, 1.05)a | 0.51 (0.15, 0.87)a | 0.44 (0.04, 0.83)a |
| Relapse rate in previous year | 0.29 (−0.12, 0.69) | 0.32 (−0.09, 0.73) | 0.53 (0.09, 0.98)a |
| Current treatment | |||
| Untreated | Reference | Reference | Reference |
| IFN | −0.41 (−0.93, 0.12) | −0.06 (−0.61, 0.49) | 0.31 (−0.29, 0.91) |
| GA | −0.57 (−1.03, −0.11)a | −0.37 (−0.85, 0.12) | −0.11 (−0.64, 0.41) |
| NTZ | −0.55 (−1.07, −0.02)a | 0.09 (−0.46, 0.64) | 0.61 (0.01, 1.21) |
| FTY | −0.80 (−1.32, −0.28)a | −0.38 (−0.92, 0.15) | −0.01 (−0.59, 0.58) |
| BG-12 | −0.08 (−0.52, 0.37) | 0.18 (−0.28, 0.64) | 0.24 (−0.26, 0.74) |
| TFL | −0.02 (−0.88, 0.83) | −0.11 (−1.05, 0.84) | −0.04 (−1.07, 0.98) |
| Other | −0.39 (−1.05, 0.28) | 0.26 (−0.43, 0.94) | 0.76 (0.02, 1.50) |
Values reported are the estimated linear regression coefficient and associated 95% confidence interval from a model with the characteristic as the predictor and likelihood of progression as the outcome. These values represent the change in the mean of the outcome for a one unit increase in the predictor. Participants with missing data on a specific covariate were not included in the analysis of that covariate (race: 8; marital status: 7; number of children: 16; EDSS: 24).
Association between predictor and covariate had a p value of less than 0.05. Since global test comparing all treatments was statistically significant for progression at two years (p = 0.036) and failed to be statistically significant for progression at five years (p = 0.26) or at 10 years (p = 0.17), pairwise treatment comparisons are starred only for progression at two years.
EDSS: Expanded Disability Status Scale; IFN: interferon; GA: glatiramer acetate; NTZ: natalizumab; FTY: fingolimod; BG-12: dimethyl fumarate; TFL: Teriflunomide.